Main > > >CORONARY ARTERY BYPASS. GRAFT. *

---

Cardio.>Arrhytmia. Atrial Fibrillation (AFi.) Treat.: RadioFrequency (RF) Abla- tion. Bipolar RF Clamps.
Persistent and Long-Standing Persistent
(Non-Paroxysmal) during Open-Heart Concomitant Coronary Artery Bypass Grafting (CABG) &/or Valve Replacement or Repair Procedures.
USA Approval Date: 2011. 12.14.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.17.




Cardio.>Aspirin+OmeprAzole Delayed Release Tablets.
Indications:
Aspirin Component:
. Reducing the combined risk of death
and nonfatal MI in patients with a
previous MI or unstable angina
pectoris
. Reducing the combined risk of MI and
sudden death in patients with chronic
stable angina pectoris
. Use in patients who have undergone
revascularization procedures (Coronary
Artery Bypass Graft [CABG] or
Percutaneous Transluminal Coronary
Angioplasty [PTCA]) when there is a
pre-existing condition for which
aspirin is already indicated
OmeprAzole Component:
. decreasing the risk of developing
aspirin-associated gastric ulcers in
patients at risk for developing
aspirin-associated gastric ulcers due
to age (≥ 55) or documented history of
gastric ulcers.
USA Approval Date: 2016. 09.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Cardio.>Post CABG (Coronary Artery Bypass Graft). Vein Graft Disease. Prevention: External Co/Cr Stent.
EU Approval Date: 2013. 02.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 02.25.


>CORONARY ARTERY BYPASS. GRAFT. *'s products
This section has no products